HC Wainwright Reiterates “Neutral” Rating for Lyell Immunopharma (NASDAQ:LYEL)

HC Wainwright reissued their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report report published on Monday morning, Benzinga reports. They currently have a $1.00 price target on the stock.

Separately, Bank of America lowered their price target on Lyell Immunopharma from $9.00 to $6.00 and set a buy rating for the company in a research note on Thursday, June 27th.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $1.45 on Monday. Lyell Immunopharma has a fifty-two week low of $1.18 and a fifty-two week high of $3.26. The stock’s 50-day moving average is $1.62 and its two-hundred day moving average is $2.10. The stock has a market cap of $369.66 million, a PE ratio of -1.61 and a beta of -0.52.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. On average, equities research analysts anticipate that Lyell Immunopharma will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Large investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $31,000. RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter worth approximately $38,000. Simplicity Wealth LLC acquired a new stake in Lyell Immunopharma in the 1st quarter worth approximately $58,000. Dimensional Fund Advisors LP lifted its holdings in Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after purchasing an additional 26,635 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Lyell Immunopharma in the 1st quarter worth approximately $64,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.